Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Stroke is a leading cause of disability and death, affecting many people each year. Rehabilitation during the first six months after stroke is crucial for recovery, but current community services often provide limited therapy. This research evaluates a 16-week home-based physiotherapy program using tele-rehabilitation to increase therapy time and improve motor and functional outcomes for stroke survivors. Participants will be randomly assigned to either the intervention or control group. Those in the intervention group will receive a personalized physiotherapy program including five home visits and four remote sessions over 16 weeks. The program uses the Giraffe platform to deliver tailored exercise plans, goal setting, action planning, and supported self-management, supported by a workbook. Control participants will receive usual multidisciplinary rehabilitation as per their NHS care plan. Participants will be assessed at four time points measuring walking ability, arm function, disability level, confidence, fatigue, and quality of life. The study will track feasibility by monitoring participation rates, exercise completion, and outcome measurements, alongside interviews with stroke survivors, carers, and therapists. The main outcome measure is the Canadian Occupational Performance Measure, with additional clinical and wellbeing assessments conducted throughout the study and follow-up at 24 weeks.
Actively Recruiting
The trial investigates treatments for bloodstream infection caused by Staphylococcus aureus SAB, which can be life-threatening with a 15-30% death rate within three months. This international, multi-center randomized adaptive platform trial aims to find the best treatment options to reduce mortality within 90 days of infection. The trial adapts over time by assigning more patients to treatments that show better outcomes and removing less effective options. Participants receive various antibiotic treatments depending on their group. These include intravenous vancomycin or daptomycin, flucloxacillin or cloxacillin, cefazolin, or benzylpenicillin, with dosages adjusted for kidney function or illness severity. Some receive adjunctive drugs like clindamycin, and others may switch from intravenous to oral antibiotics if eligible after 7 or 14 days. Additionally, some participants undergo PETCT scans as part of the study. During the study, participants are monitored closely with blood cultures, temperature checks, and clinical assessments to track infection clearance and complications. Researchers measure all-cause mortality at 90 days as the primary outcome, along with other outcomes such as survival at earlier time points, hospital stay length, microbiological treatment failure, serious reactions, and antibiotic use. Safety and health economic data are also collected to evaluate treatments comprehensively throughout the trial.
Actively Recruiting
Aortic stenosis AS affects many older adults, with a rising number of people over 65 and 75 years old experiencing moderate to severe disease. This study aims to compare the benefits of early aortic valve replacement AVR versus expectant management in patients with severe asymptomatic AS. It addresses a significant gap, as no randomized controlled trials have yet compared these approaches to determine which leads to better outcomes and cost-effectiveness. Participants will be randomly assigned to either early AVR, where surgery or transcatheter AVR TAVI is planned within six months, or to expectant management, involving regular monitoring according to standard hospital practice. The study will be conducted across multiple centers in the UK, Australia, and New Zealand, with an internal pilot phase to confirm recruitment feasibility. Those in the AVR group may undergo additional tests such as coronary angiography, with further treatment decisions made by their care team. During the study, participants will be followed for a median of 5.5 years, with assessments including cardiovascular events, hospitalizations, quality of life questionnaires, and health economics evaluations. Researchers will measure a combined outcome of cardiovascular death, heart failure hospitalization, and stroke, along with other health and disability measures. The study will use intention-to-treat analysis, ensuring participants are evaluated in their assigned groups regardless of treatment received.